NR3C2 and heart failure: The findings from this study highlight significant gaps in the prescription of essential therapies for patients with heart failure and reduced ejection fraction (HFrEF), particularly concerning mineralocorticoid receptor antagonists (MRAs) and angiotensin receptor–neprilysin inhibitors (ARNI).